AR096277A1 - Composiciones de vacuna que comprenden oligonucleótidos inmunoestimulantes - Google Patents
Composiciones de vacuna que comprenden oligonucleótidos inmunoestimulantesInfo
- Publication number
- AR096277A1 AR096277A1 ARP140101927A ARP140101927A AR096277A1 AR 096277 A1 AR096277 A1 AR 096277A1 AR P140101927 A ARP140101927 A AR P140101927A AR P140101927 A ARP140101927 A AR P140101927A AR 096277 A1 AR096277 A1 AR 096277A1
- Authority
- AR
- Argentina
- Prior art keywords
- oligonucleotides
- vaccine compositions
- oil
- antigen
- include immuno
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición de vacuna que comprende un componente antigénico y un componente coadyuvante, en la que el componente coadyuvante comprende un oligonucleótido inmunoestimulante de clase P y o bien una combinación de una saponina y un esterol; o bien una fase oleosa que comprende un aceite y, opcionalmente, uno o más emulsionantes, comprendiendo dicha fase oleosa un 2 - 20% v/v de la composición de vacuna, en la que dicho componente antigénico es un antígeno de EHV o un antígeno de Leishmania. Reivindicación 4: La composición de vacuna de una cualquiera de las reivindicaciones 1 - 3, caracterizada porque la saponina, si está presente, es Quil A, el esterol, si está presente, es colesterol y el aceite, si está presente, es aceite SP.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361823189P | 2013-05-14 | 2013-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096277A1 true AR096277A1 (es) | 2015-12-16 |
Family
ID=50897961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101927A AR096277A1 (es) | 2013-05-14 | 2014-05-13 | Composiciones de vacuna que comprenden oligonucleótidos inmunoestimulantes |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP3542819B1 (es) |
JP (2) | JP6505084B2 (es) |
CN (2) | CN105263518B (es) |
AR (1) | AR096277A1 (es) |
AU (2) | AU2014265649B2 (es) |
BR (1) | BR112015028748A2 (es) |
CA (2) | CA3027289A1 (es) |
DK (1) | DK3542819T3 (es) |
ES (2) | ES2742325T3 (es) |
HK (1) | HK1219426A1 (es) |
HR (1) | HRP20211452T1 (es) |
HU (1) | HUE056040T2 (es) |
LT (1) | LT3542819T (es) |
MX (2) | MX367268B (es) |
PL (1) | PL3542819T3 (es) |
PT (2) | PT3542819T (es) |
RU (1) | RU2627447C2 (es) |
SI (1) | SI3542819T1 (es) |
WO (1) | WO2014186291A1 (es) |
ZA (1) | ZA201507774B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2878475T3 (es) * | 2015-07-20 | 2021-11-18 | Zoetis Services Llc | Composiciones adyuvantes liposomales |
US10456459B2 (en) * | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
BE1023538B1 (fr) * | 2016-04-22 | 2017-04-26 | Sil'innov Scrl | Silices mésoporeuses et leur procédé de synthèse |
TW202206098A (zh) * | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7904021A (nl) * | 1979-05-22 | 1980-04-29 | Gist Brocades Nv | Gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen door adeno achtige virussen veroorzaakte eiproduktiedalingen en door reo virus veroorzaakte ziekteverschijnselen. |
US6803041B2 (en) * | 2001-03-20 | 2004-10-12 | Boehringer Ingelheim Vetmedica, Inc. | Equine herpesvirus vaccine |
CN1935258B (zh) * | 2001-07-27 | 2013-04-03 | 惠氏公司 | 西尼罗河疫苗 |
JP2005532067A (ja) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 刺激性免疫応答用の核酸組成物 |
GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
PT2078080E (pt) * | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
DK2086582T3 (da) * | 2006-10-12 | 2013-02-04 | Glaxosmithkline Biolog Sa | Vaccine omfattende en olie-i-vand-emulsionsadjuvans |
DK2575878T3 (en) * | 2010-05-28 | 2018-08-13 | Zoetis Belgium S A | VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES |
EA201390676A1 (ru) * | 2010-11-08 | 2013-11-29 | Инфекшес Дизиз Рисерч Инститьют | Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза |
-
2014
- 2014-05-12 EP EP19173426.8A patent/EP3542819B1/en active Active
- 2014-05-12 CA CA3027289A patent/CA3027289A1/en not_active Abandoned
- 2014-05-12 MX MX2015015758A patent/MX367268B/es active IP Right Grant
- 2014-05-12 CN CN201480027344.XA patent/CN105263518B/zh active Active
- 2014-05-12 ES ES14729191T patent/ES2742325T3/es active Active
- 2014-05-12 PL PL19173426T patent/PL3542819T3/pl unknown
- 2014-05-12 DK DK19173426.8T patent/DK3542819T3/da active
- 2014-05-12 PT PT191734268T patent/PT3542819T/pt unknown
- 2014-05-12 CA CA2911938A patent/CA2911938C/en active Active
- 2014-05-12 AU AU2014265649A patent/AU2014265649B2/en active Active
- 2014-05-12 JP JP2016514012A patent/JP6505084B2/ja active Active
- 2014-05-12 RU RU2015146752A patent/RU2627447C2/ru active
- 2014-05-12 BR BR112015028748A patent/BR112015028748A2/pt not_active Application Discontinuation
- 2014-05-12 HU HUE19173426A patent/HUE056040T2/hu unknown
- 2014-05-12 SI SI201431889T patent/SI3542819T1/sl unknown
- 2014-05-12 EP EP14729191.8A patent/EP2996719B1/en active Active
- 2014-05-12 ES ES19173426T patent/ES2894138T3/es active Active
- 2014-05-12 HR HRP20211452TT patent/HRP20211452T1/hr unknown
- 2014-05-12 PT PT14729191T patent/PT2996719T/pt unknown
- 2014-05-12 WO PCT/US2014/037705 patent/WO2014186291A1/en active Application Filing
- 2014-05-12 CN CN201810130911.4A patent/CN108079290A/zh active Pending
- 2014-05-12 LT LTEP19173426.8T patent/LT3542819T/lt unknown
- 2014-05-13 AR ARP140101927A patent/AR096277A1/es unknown
-
2015
- 2015-10-16 ZA ZA2015/07774A patent/ZA201507774B/en unknown
- 2015-11-13 MX MX2019009407A patent/MX2019009407A/es unknown
-
2016
- 2016-06-28 HK HK16107491.1A patent/HK1219426A1/zh unknown
-
2017
- 2017-09-25 AU AU2017232231A patent/AU2017232231A1/en not_active Abandoned
-
2019
- 2019-01-31 JP JP2019015717A patent/JP2019108328A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200035I1 (hu) | Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik | |
ZA201903620B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
CO2017003396A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
CL2016000650A1 (es) | Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento. | |
CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
BR112017013661A8 (pt) | Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
AR096277A1 (es) | Composiciones de vacuna que comprenden oligonucleótidos inmunoestimulantes | |
BRPI1013780A2 (pt) | composições para imunização contra staphylococcus aureus. | |
MX2020004367A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
BR112017000313A2 (pt) | sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
BR112015004515A2 (pt) | composição imunogênica | |
BR112019004303A2 (pt) | composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma | |
BR112016015078A2 (pt) | método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica | |
BR112019011286A2 (pt) | métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina. | |
AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante | |
BR112016030728A2 (pt) | método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença | |
BR112016012393A2 (pt) | Vacina, e, uso de uma combinação de um vírus prrs atenuado vivo e um antígeno de lawsonia intracellularis inativado | |
BR112014023092A8 (pt) | Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit | |
BR112017012938A2 (pt) | uso por via oral de uma composição e método para aprimorar a aparência da celulite | |
BR112015012515A2 (pt) | métodos para a indução de anticorpos | |
BR112016028909A2 (pt) | método e dispositivo para fechamento de tecidos | |
AR113832A1 (es) | Vacunas contra el zika, composiciones inmunogénicas y métodos que las utilizan | |
BR102017027757A2 (pt) | processo de obtenção da vacina meningocócica, vacina meningocócica e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |